DE69434743D1 - Polymermatrize und ihre verwendung in pharmazeutischen zusammensetzungen - Google Patents

Polymermatrize und ihre verwendung in pharmazeutischen zusammensetzungen

Info

Publication number
DE69434743D1
DE69434743D1 DE69434743T DE69434743T DE69434743D1 DE 69434743 D1 DE69434743 D1 DE 69434743D1 DE 69434743 T DE69434743 T DE 69434743T DE 69434743 T DE69434743 T DE 69434743T DE 69434743 D1 DE69434743 D1 DE 69434743D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
polymermatrize
carbomate
tnf
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434743T
Other languages
English (en)
Other versions
DE69434743T2 (de
Inventor
Murat Acemoglu
Siegfried Bantle
David Bodmer
Salvatore Cammisuli
Peter Hiestand
Fritz Nimmerfall
Georg Stoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939317822A external-priority patent/GB9317822D0/en
Priority claimed from GB939320240A external-priority patent/GB9320240D0/en
Priority claimed from GB939325900A external-priority patent/GB9325900D0/en
Priority claimed from GB9407156A external-priority patent/GB9407156D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69434743D1 publication Critical patent/DE69434743D1/de
Application granted granted Critical
Publication of DE69434743T2 publication Critical patent/DE69434743T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/18—Block or graft polymers
    • C08G64/183—Block or graft polymers containing polyether sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/02—Aliphatic polycarbonates
    • C08G64/0208—Aliphatic polycarbonates saturated
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/20—General preparatory processes
    • C08G64/32—General preparatory processes using carbon dioxide
    • C08G64/34—General preparatory processes using carbon dioxide and cyclic ethers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69434743T 1993-08-27 1994-08-26 Polymermatrize und ihre verwendung in pharmazeutischen zusammensetzungen Expired - Lifetime DE69434743T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB939317822A GB9317822D0 (en) 1993-08-27 1993-08-27 Organic compounds
GB9317822 1993-08-27
GB9320240 1993-10-01
GB939320240A GB9320240D0 (en) 1993-10-01 1993-10-01 Improvements in or relating to organic compounds
GB9325900 1993-12-17
GB939325900A GB9325900D0 (en) 1993-12-17 1993-12-17 Organic compounds
GB9407156 1994-04-11
GB9407156A GB9407156D0 (en) 1994-04-11 1994-04-11 Organic compounds
PCT/EP1994/002833 WO1995006077A2 (en) 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69434743D1 true DE69434743D1 (de) 2006-06-29
DE69434743T2 DE69434743T2 (de) 2006-11-16

Family

ID=27451062

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434743T Expired - Lifetime DE69434743T2 (de) 1993-08-27 1994-08-26 Polymermatrize und ihre verwendung in pharmazeutischen zusammensetzungen

Country Status (24)

Country Link
US (2) US6083521A (de)
EP (2) EP1028137A3 (de)
JP (2) JP3343124B2 (de)
KR (1) KR100341995B1 (de)
CN (3) CN1326568C (de)
AT (1) ATE327273T1 (de)
AU (1) AU697995B2 (de)
BR (1) BR9407370A (de)
CA (1) CA2168012C (de)
CZ (1) CZ55296A3 (de)
DE (1) DE69434743T2 (de)
DK (1) DK0719295T3 (de)
ES (1) ES2262135T3 (de)
FI (1) FI960892A (de)
HU (1) HU220637B1 (de)
IL (1) IL110787A0 (de)
NO (2) NO960721L (de)
NZ (1) NZ273319A (de)
PL (1) PL182569B1 (de)
PT (1) PT719295E (de)
SG (2) SG87847A1 (de)
SK (1) SK25496A3 (de)
TW (1) TW492863B (de)
WO (1) WO1995006077A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6756060B1 (en) 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6100372A (en) * 1998-08-20 2000-08-08 Akzo Nobel Nv Monocarboxylic acid-terminated polymers of carbon dioxide and an alkylene oxide
US6663878B1 (en) 1999-04-29 2003-12-16 Usbiomaterials Corp. Anti-inflammatory bioactive glass particulates
ATE302621T1 (de) 1999-06-14 2005-09-15 Imp College Innovations Ltd Silberhaltige bioglas-zusammensetzungen, die von sol-gel zuständen abgeleitet werden
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
AU2001283304B2 (en) * 2000-08-11 2005-05-05 Favrille, Inc. Method and composition for altering a T cell mediated pathology
CA2453050A1 (en) * 2000-09-06 2002-03-14 A.P. Pharma, Inc. Degradable polyacetal polymers
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
JP2005516586A (ja) * 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
CA2476556A1 (en) 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2003088818A2 (en) 2002-04-18 2003-10-30 Mnemoscience Gmbh Biodegradable shape memory polymeric sutures
NZ537816A (en) * 2002-08-08 2007-06-29 Baylor College Medicine An autologous T cell vaccine for the treatment of multiple sclerosis
EP2301573A1 (de) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen gegen Krebs und Infektionskrankheiten und Anwendungsverfahren dafür
GB0228571D0 (en) * 2002-12-06 2003-01-15 Novartis Ag Organic compounds
KR20070015113A (ko) * 2003-12-24 2007-02-01 노파르티스 아게 제약 조성물
SI1949915T1 (sl) * 2004-04-30 2012-12-31 Biopheresis Technologies, Inc. Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
WO2006100844A1 (ja) * 2005-03-18 2006-09-28 Mitsui Chemicals, Inc. 生分解性を有する水環境応答型ポリマー、その製造方法および水崩壊性材料
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
ES2383303T3 (es) 2005-11-10 2012-06-20 Chemi S.P.A. Formulaciones de inhibidores de la liberación prolongada de la hormona del crecimiento análogos de la somatostatina
JP2009536036A (ja) * 2006-05-05 2009-10-08 オペクサ セラピューティクス Ｔ細胞ワクチン
WO2008054725A2 (en) * 2006-10-31 2008-05-08 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
BRPI0919323A8 (pt) 2008-09-08 2018-02-14 Saudi Aramco Tech Co Métodos e composições de poliol polocarbonato
AU2009336723B2 (en) * 2008-12-15 2013-06-06 Novartis Ag Nanoparticle compositions
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
IN2014CN01299A (de) 2011-07-25 2015-04-24 Novomer Inc
TR201202779A2 (tr) 2012-03-12 2013-10-21 Petkim Petrokimya Holding Anonim Sirketi Polietilen karbonat üretim yöntemi.
EP2664641B1 (de) 2012-05-18 2018-04-25 Petkim Petrokimya Holding Anonim Sirekti Verfahren zur herstellung von polyethylencarbonat mit metallsalzen
WO2013177546A2 (en) * 2012-05-24 2013-11-28 Novomer, Inc. Polycarbonate polyol compositions and methods
EP2917257B1 (de) 2012-11-07 2019-09-11 Saudi Aramco Technologies Company Hochfeste polyurethanschaumzusammensetzungen und verfahren
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
SG11202006985TA (en) * 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2020028606A1 (en) 2018-08-02 2020-02-06 Saudi Aramco Technologies Company Sustainable polymer compositions and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3585168A (en) * 1968-09-21 1971-06-15 Shohei Inoue Process for producing copolymer of epoxide and carbon dioxide
US3706713A (en) * 1970-08-11 1972-12-19 Shell Oil Co Aliphatic polycarbonates
JPS5341117B2 (de) * 1971-12-21 1978-10-31
US3953383A (en) * 1972-07-21 1976-04-27 Nippon Oil Seal Industry Co., Ltd. Catalytic process for copolymerizing epoxy compounds with carbon dioxide
JPS553288B2 (de) * 1973-08-06 1980-01-24
JPS5761769B2 (de) * 1974-03-20 1982-12-25 Nippon Oil Seal Ind Co Ltd
JPS5922731B2 (ja) * 1975-09-12 1984-05-29 エヌオーケー株式会社 共重合用触媒の製造法
JPS5438397A (en) * 1977-08-31 1979-03-22 Hidetoshi Tsuchida Copolymerization catalyst consisting of carbon dioxide and oxirane compoud
US4379138A (en) * 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
US4665136A (en) * 1986-04-07 1987-05-12 Air Products And Chemicals, Inc. Process for producing novel block alkylene polycarbonate copolymers
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4783445A (en) * 1987-12-14 1988-11-08 Arco Chemical Company Soluble epoxide/carbon dioxide copolymerization catalysts
US5274074A (en) * 1987-12-17 1993-12-28 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
DE3853591T2 (de) * 1987-12-17 1995-09-14 United States Surgical Corp Medizinische anordnungen, hergestellt aus homo- und kopolymeren mit wiederkehrender karbonateinheiten.
US4789727A (en) * 1987-12-18 1988-12-06 Arco Chemical Company Reduction of catalyst usage in epoxide/CO2 polymerization
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
EP0358326B1 (de) * 1988-08-09 1996-12-27 Mitsui Petrochemical Industries, Ltd. Verfahren zur Herstellung eines zinkhaltigen festen Katalysators und Verfahren zur Herstellung von Polyalkylencarbonat
EP0374510B1 (de) * 1988-12-19 1997-01-15 American Cyanamid Company Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
US4999417A (en) * 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
US4960862A (en) * 1989-03-31 1990-10-02 Air Products And Chemicals, Inc. Regeneration of metallo-organic catalyst for carbon dioxide-epoxide copolymerization
US5026676A (en) * 1989-06-07 1991-06-25 Air Products And Chemicals, Inc. Catalyst for the copolymerization of epoxides with CO2
US4943677A (en) * 1989-06-08 1990-07-24 Air Products And Chemicals, Inc. Making poly(alkylene carbonates) of controlled molecular weight
JP2693584B2 (ja) * 1989-06-26 1997-12-24 三井石油化学工業株式会社 ポリアルキレンカーボネート製造用触媒成分の製造方法
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
JP2930362B2 (ja) * 1990-04-09 1999-08-03 東ソー株式会社 感作ｔ細胞関与疾患の治療剤
EP0466986B1 (de) * 1990-07-02 1994-04-27 Bend Research, Inc. Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0486437B1 (de) * 1990-11-13 1997-07-09 ISTITUTO SIEROVACCINOGENO ITALIANO I.S.I. S.p.A. Funktionelle Polyester aus Glycidylderivaten und cyclischen Anhydriden oder Kohlendioxid
JPH07503700A (ja) * 1991-01-03 1995-04-20 アルカーメス　コントロールド　セラピューティックス，　インコーポレイテッド カチオン生体ポリマーによるタンパク質の安定化
CA2060635A1 (en) * 1991-02-12 1992-08-13 Keith D'alessio Bioabsorbable medical implants
IT1248061B (it) * 1991-06-14 1995-01-05 Mediolanum Farmaceutici Spa Policarbonati e loro uso per la preparazione di matrici bioerodibili
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
JPH05194253A (ja) * 1992-01-16 1993-08-03 Kirin Brewery Co Ltd 水溶性ポリペプチドホルモンを含む徐放性微小粒子状製剤及びその製造法
GB9206736D0 (en) * 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
JP3028227B1 (ja) 1998-12-15 2000-04-04 穎助 藤本 デスポーザル無針注射器

Also Published As

Publication number Publication date
JP3343124B2 (ja) 2002-11-11
DK0719295T3 (da) 2006-09-25
EP0719295B1 (de) 2006-05-24
AU7655794A (en) 1995-03-21
EP0719295A1 (de) 1996-07-03
HUT74568A (en) 1997-01-28
PT719295E (pt) 2006-10-31
US6083521A (en) 2000-07-04
ATE327273T1 (de) 2006-06-15
CA2168012C (en) 2005-08-09
TW492863B (en) 2002-07-01
JP2003002844A (ja) 2003-01-08
JP4477813B2 (ja) 2010-06-09
NO20021141L (no) 1996-04-26
FI960892A0 (fi) 1996-02-26
IL110787A0 (en) 1994-11-11
US6262127B1 (en) 2001-07-17
HU220637B1 (hu) 2002-03-28
CN1258551C (zh) 2006-06-07
CN1129947A (zh) 1996-08-28
SG87847A1 (en) 2002-04-16
JPH09501967A (ja) 1997-02-25
EP1028137A3 (de) 2000-11-02
CZ55296A3 (en) 1996-09-11
CN1344755A (zh) 2002-04-17
AU697995B2 (en) 1998-10-22
DE69434743T2 (de) 2006-11-16
CN1506116A (zh) 2004-06-23
FI960892A (fi) 1996-04-18
NO960721L (no) 1996-04-26
CN1326568C (zh) 2007-07-18
KR100341995B1 (ko) 2002-11-23
NZ273319A (en) 1998-02-26
CA2168012A1 (en) 1995-03-02
EP1028137A2 (de) 2000-08-16
SK25496A3 (en) 1997-03-05
WO1995006077A2 (en) 1995-03-02
HU9600456D0 (en) 1996-04-29
CN1085687C (zh) 2002-05-29
ES2262135T3 (es) 2006-11-16
NO20021141D0 (no) 2002-03-07
BR9407370A (pt) 1996-07-16
WO1995006077A3 (en) 1995-05-04
SG50724A1 (en) 1999-10-19
PL182569B1 (pl) 2002-01-31
NO960721D0 (no) 1996-02-23
PL312717A1 (en) 1996-05-13

Similar Documents

Publication Publication Date Title
DE69434743D1 (de) Polymermatrize und ihre verwendung in pharmazeutischen zusammensetzungen
NO20002547D0 (no) Poly(vinylamin)-baserte superabsorberende geler og fremgangsmÕte for fremstilling derav
PT1474425E (pt) Desazapurinas e sua utilizacao
CA2106079A1 (en) Pegylation of polypeptides
ES2167784T3 (es) Copolimeros reticulados a base de polimeros policarboxilicos.
ATE304355T1 (de) Pharmazeutische zusammensetzungen, enthaltend pyridin- oder pyrimidin-derivate, zur hemmung der produktion und sekretion von cytokinen
ES2145013T3 (es) Formulaciones de coagulo de sangre-matriz polimera de proteinas osteogenicas.
DE60237241D1 (de) Medizinische geräte, die rapamycinanaloga enthalten
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
ES2094359T3 (es) Formulaciones farmaceuticas de proteinas osteogenicas.
DE602004001857D1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
FR2799196B1 (fr) Copolymeres reticules a base de copolymeres polycarboxyliques non reticules
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
CA2474988A1 (en) Polymeric matrices and their uses in pharmaceutical compositions
ATE288924T1 (de) Tnf inhibierendes protein tip-b1 und dessen verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN